Skip to main content
. 2021 Nov 25;12:6889. doi: 10.1038/s41467-021-27108-8

Fig. 4. Inflammation associated with A3250 tumors by immunostaining analysis.

Fig. 4

a, b CD45 IHC staining of tumors at four-weeks as indicated. c, d Immunofluorescent staining of the skin adjacent to A3250 tumors for CD45 (red) and lymphatic marker LYVE-1 (green) at three-weeks (DAPI, blue). Note dense inflammatory infiltrate in the dermis and the absence of tumor cells within the lymphatics at this time point. e, f Immunofluorescent staining of A3250 tumor (GFP, green) for CD45 (red) at one-week post-injection. g, h Immunofluorescent staining of A3250 tumor for F4/80 macrophage marker (red) and cytokeratin (green) at four weeks as indicated. i Skin adjacent to A3250 tumor immunostained for F4/80. j, k Immunostainining of SUM149 tumor (GFP, green) for F4/80 (red) at four-weeks. l, m Iba1 IHC staining of tumors at four-weeks as indicated. Images are representative of three independent experiments. n = 3 biologically independent mice. Scale bars: 100 μm.